
Acurx and Leiden UMC will publish MRSA PolC structural results that reshape PolC inhibitor design priorities.
Antibiotic resistance remains a high-stakes public health threat; structural biology that clarifies drug binding can shorten the path from discovery to viable candidates.
AI reasoning
Antibiotic resistance remains a high-stakes public health threat; structural biology that clarifies drug binding can shorten the path from discovery to viable candidates.
Curated summary
Acurx Pharmaceuticals announced a scientific partnership with Leiden University Medical Center in the Netherlands. The project will study the 3D structure of PolC from MRSA with DNA and an Acurx inhibitor, aiming to accelerate development of antibiotics against resistant Gram-positive pathogens. The work builds on a November 2025 Health-Holland grant and earlier research published in Nature Communications.
Supporting evidence
YouTube·WebsEdgeMedicineBroadly Focussed Translational Genetics Research - Leiden University Medical Center, The Netherlands
832 engagements1h ago
YouTube·New to The Street TVAcurx Pharma Partners With Leiden University to Advance Next-Generation Antibiotics
551 engagements1h ago
YouTube·Leids Universitair Medisch CentrumHypoVax
117 engagements1h ago
YouTube·Leids Universitair Medisch CentrumLUMC Planetaire gezondheid en duurzaamheid in het onderwijs ENG
112 engagements1h ago
YouTube·Civil CouncilFloor van der Does, - Leiden University Medical Center
90 engagements1h ago
YouTube·WebsEdgeMedicineCenter for Endocrine Tumors Leiden – Leiden University Medical Center
1h ago
YouTube·Universiteit Leiden360 Tour Leiden University Medical Center - Leiden University
1h ago
YouTube·New to The Street TVAcurx Pharmaceuticals (NASDAQ: ACXP) Announces Breakthrough in Antibiotic Innovation
1h ago
Source news
Acurx partners with Leiden University Medical Center to map MRSA target and speed antibiotic development
The collaboration aims to determine the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor.



















